Oncotarget New Insights into HER2-Mutated Non-Small Cell Lung Cancer in Brazil In non–small cell lung cancer (NSCLC), alterations in the HER2 (ERBB2) gene define a... read more October 8, 2025
Oncotarget Amivantamab Monotherapy in Rare EGFR-Mutated Advanced NSCLC Amivantamab, an anti-EGFR/MET bispecific antibody, shows efficacy in EGFR-mutated NSCLC, but its role in... read more August 26, 2025
Oncotarget Cigarette Smoke and Weak DNA Repair: A Double Hit Behind Lung Cancer Risk Lung cancer remains the leading cause of cancer-related fatalities in the United States and worldwide,... read more August 11, 2025
Oncotarget A Rare Genetic Shift That Helped Lung Cancer Evade Treatment This case adds to the literature on bypass signaling as a mechanism of resistance to... read more March 12, 2025
Oncotarget Small Cell Lung Cancer: Advancing Precision Medicine with Biomarker Research Precision medicine is an innovative approach to disease prevention and treatment that considers differences in... read more December 4, 2024
Oncotarget Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations This article dissects Dr. Mikhail V. Blagosklonny’s paradigm-shifting perspective on preemptive combinations for treating... read more June 6, 2024
Oncotarget The Obesity Paradox, Metformin and Lung Cancer In a new editorial, researchers from Instituto Nacional de Cancerología discuss the "obesity paradox"... read more July 27, 2023
Oncotarget New Target Fights Ferroptosis- and Radio-Resistance in Lung Cancers Researchers published a research perspective about a recent study that uncovered FSP1 as a novel... read more November 2, 2022
Oncotarget Trending With Impact: Analysis of Mutational Burden in NSCLC Researchers conducted a multi-site cohort study of tumor mutational burden among hundreds of patients diagnosed... read more April 21, 2022
Oncotarget New Study: ALK Rearrangement Among Lung Cancer Patients In Oncotarget’s Volume 12, Issue 23, cover paper, researchers retrospectively assessed the prevalence of... read more November 10, 2021